|Videos|March 4, 2021

Find out more about Allergan’s presbyopia drop NDA filing

Author(s)Gretchyn M. Bailey, NCLC, FAAO, Editor in Chief, Content Channel Director, Michael Robinson, MD

Potential presbyopia treatment coming

Learn more about the recent new drug application (NDA) Allergan submitted for its investigational eyedrop to treat presbyopia. Optometry Times® Editor in Chief Gretchyn Bailey, NCLC, FAAO, chats with Michael Robinson, MD, vice president, global therapeutic area head of ophthalmology at Allergan, to get details on when ODs could discuss a potential presbyopia treatment with their patients.

Click here to read this interview's transcript

Click here to listen to this interview's podcast

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Find out more about Allergan’s presbyopia drop NDA filing

Related Content

Practical tips and tricks: Drs Jeffrey J. Walline, Erin Tomiyama weigh in on myopia management

TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis

Recent study findings may prove previous estimations of retinal cell communication, low-light vision

Hybrid AI model distinguishes keratoconus from healthy eyes with 90% accuracy

Georgia university receives state funding for state's first college of optometry

Latest CME

(CME Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Neurotrophic Keratitis Insights: An Interactive Corneal Sensitivity Testing Workshop

(COPE Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Retina Updates in Montréal

PER Global Perspectives: The TROP2-Targeted ADC Landscape in NSCLC and How to Interpret the Evidence

Rapid Reviews in Retina™: Emerging Updates from Spring 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Interventional Dry Eye: A Stepwise Treatment & Management Approach

(CME Track) Rapid Reviews in Retina™: Emerging Updates from Summer 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) Community Collaborative Connections™: Optimizing the Collaborative Care of Neovascular Retinal Disease in a New Age of Treatment

(CME Track) A Forward Look at Anti-VEGF Therapies: A Paradigm Shift in Neovascular Retinal Disease Management

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

Rapid Reviews in Retina™: Emerging Updates from Fall 2025—Addressing the Wealth of New Data in Treatments for Neovascular Retinal Disease

Trending on Optometry Times - Clinical News & Expert Optometrist Insights

Practical tips and tricks: Drs Jeffrey J. Walline, Erin Tomiyama weigh in on myopia management

Georgia university receives state funding for state's first college of optometry

Bausch + Lomb launches preservative-free version of Blink Triple Care eye drops

TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis

Exercise for the prevention and mitigation of eye disease